LUKAS Business Summary

Lukas Biomedical Inc. (6814.TWO) operates a high-growth biotechnology model focused on autologous cell therapy, precision diagnostics, and biotech-enhanced consumer goods. The company’s core value proposition is the LuLym-T platform, a memory T-cell technology licensed from Japan’s Lymphotec (a GC Cell subsidiary), which targets solid tumors such as liver and head-and-neck cancers. Revenue is diversified across clinical cell-processing services, Circulating Tumor Cell (CTC) diagnostic testing, and the "FreshO2" biotech cosmetic brand, which provides stable cash flow to fund its R&D pipeline. Following the 2026 implementation of Taiwan’s Regenerative Medicine Act, Lukas has positioned itself as a frontrunner for conditional market approval, competing directly with Medigen Biotechnology, GNTbm, and Bionet. It maintains a unique market niche by utilizing "Memory T-cell" culture technology that offers superior persistence and lower exhaustion compared to standard CIK therapies. The executive leadership is anchored by Chairman Dr. Eric Tang (Tang-Chih Tang) and General Manager Liu Chun-Lan, who together have steered the company from its 2014 inception to its current status on the TPEx. Dr. Tang provides the clinical vision, while Liu oversees the commercial integration of the company’s medical and retail segments. The leadership is supported by a high-caliber scientific board, including Academician Dr. Lu-Hai Wang, a renowned expert in cancer biology. Lukas’s strategic position is further strengthened by its ongoing international cooperation agreement with Korea’s GC Cell, which facilitates the exchange of clinical data and regulatory expertise. This partnership, combined with deep-rooted collaborations with top-tier institutions like Taipei Veterans General Hospital and National Taiwan University Hospital, ensures a robust pipeline and a sophisticated governance structure backed by significant medical and academic pedigree.